The Italian "Study"
First of all, KIDS DO NOT TRY THIS AT HOME, it is possible to "fracture" the rigid penis, which results in a trip to the ER and then the OR in short order. One of the urologists on the thread may give you the details.
Second, the "Research Letter" is mentioned but not available in full text on the web version of The Lancet, perhaps some one can scan it from the print version, or call the good doctor below and get the E-Mail. I suspect the negative spin was more in the Reuters report than in the Lancet. We should reserve judgement until we see the actual print of the letter and find out who funded it. Obviously, the Reuters report was written by someone with no scientific background in view of the "one kilogram is about a half a pound" statement.
Since many of these men, by report, were prior users of injection therapy, it may have been funded from Caverject to help prevent defection from the needle to the suppository.
This is from the press site of the lancet web site.
FURTHER TESTING OF DRUG FOR IMPOTENCE (p 1682)
Doctors from Italy report in a Research Letter in The Lancet that a drug called alprostadil can improve penile function. 123 men underwent tests with this drug and improvement in blood flow into erectile arteries of the penis was shown in all patients and an increase in penis volume in almost all patients.
The drug was inserted into the urethra, and its passage into the penile arteries followed. Dr Ermanno Greco and Dr Paolo Polonio-Balbi from Rome, Italy, measured the rigidity of the penis by a penile buckling test rather than the "Erection Assessment Scale" that has been used to evaluate this drug in the past. The buckling test was positive when a weight of 1 kg did not buckle the organ, and was judged complete when pressure within the penis was 75 mm Hg after visual erotic stimulation. Of the 123 men investigated, 11 had complete penile rigidity and 16 a full, but not lasting, erection. The increase in penis volume found was not related to hardness.
Contact: Dr Ermanno Greco, Centre for Impotence and Fertility,
Rome, Italy; tel +39 6 884 2213.
I personally expect no effect on the stock price from this report.
Zebra |
